Het beloop van bloedeigenschappen tijdens ECLS
- Conditions
- ECLS, ECMO, adults, coagulation
- Registration Number
- NL-OMON29222
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
All adult patients who start with ECLS in the ICU (according to the guidelines, ECLS can be considered in acute severe heart or lung failure with high mortality risk despite optimal conventional therapy).
Exclusion Criteria
-Pregnancy
-Start of ECLS not in the ICU, e.g. after cardiothoracic surgery
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Red blood cell aggregation and elongation (deformability) assessed by a laser assisted optical rotational cell analyzer (LORCA) on days 1-3, and within 24 hours after weaning of ECLS
- Secondary Outcome Measures
Name Time Method Red blood cell aggregation and elongation (deformability) assessed by a LORCA on 5, 7, 10, 14, 21 (when appropriate) and within 24 hours after weaning of ECLS.<br /><br><br /><br>Platelet aggregation assessed by the multiple platelet function analyzer (Multiplate) on days 1, 2, 3, 5, 7, 10, 14, 21 (when appropriate) and within 24 hours after weaning of ECLS.<br /><br><br /><br>Aditional coagulation parameters on days 1, 2, 3, 5, 7, 10, 14, 21 (when appropriate) and within 24 hours after weaning of ECLS.<br>